Grufity logoGrufity logo

Editas Medicine Inc Stock Research

EDIT

8.49USD+0.06(+0.71%)Market Closed

Market Summary

USD8.49+0.06
Market Closed
0.71%

EDIT Stock Price

EDIT RSI Chart

EDIT Valuation

Market Cap

584.5M

Price/Earnings (Trailing)

-2.65

Price/Sales (Trailing)

29.65

Price/Free Cashflow

-3.22

EDIT Price/Sales (Trailing)

EDIT Profitability

Return on Equity

-61.12%

Return on Assets

-42.86%

Free Cashflow Yield

-31.05%

EDIT Fundamentals

EDIT Revenue

Revenue (TTM)

19.7M

Revenue Y/Y

-47.58%

Revenue Q/Q

1.35%

EDIT Earnings

Earnings (TTM)

-220.4M

Earnings Y/Y

-46.58%

Earnings Q/Q

-8.99%

Price Action

52 Week Range

7.4821.60
(Low)(High)

Last 7 days

-4.1%

Last 30 days

-15.6%

Last 90 days

-15.8%

Trailing 12 Months

-43.5%

EDIT Financial Health

Current Ratio

5.94

EDIT Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-3.21

Peers (Alternatives to Editas Medicine)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
125.3B
26.3B
-2.75% 3.76%
19.12
4.76
1.32% 11.18%
99.6B
27.3B
-8.96% 41.01%
21.68
3.65
-0.09% -26.23%
58.4B
19.3B
-12.76% 1.00%
6.99
3.03
4.29% -31.47%
38.3B
10.2B
-9.67% 32.94%
12.57
3.76
-7.36% 95.80%
MID-CAP
9.1B
1.5B
-9.09% 3.35%
58.87
6.11
31.34% 72.43%
3.2B
108.5M
-21.10% -19.55%
-9.78
29.38
122.90% -12.19%
2.5B
60.9M
-18.47% -36.46%
-8.76
41.55
17.51% 22.00%
2.1B
107.9M
22.95% 67.45%
-4.29
19.27
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-14.86% -46.41%
-4.63
11.04
-70.76% -603.77%
1.1B
7.0M
-22.18% 24.65%
-7.11
158.97
131.81% -45.39%
541.9M
96.3M
-12.99% -82.24%
-1.92
5.63
72.44% -32.79%
513.7M
2.0B
-39.67% -92.01%
-0.78
0.26
72.89% 62.27%
355.3M
111.3M
-30.55% -58.78%
-1.85
3.19
0.54% -7.86%
101.4M
159.0K
-16.47% -82.96%
-0.97
637.62
-86.46% -64.56%
25.1M
-
94.03% -77.12%
-0.31
3.21
0.51% -185.61%

Financials for Editas Medicine

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-23.5%20.0026.0032.0029.0026.00
Operating Expenses6.9%246230218213219
  S&GA Expenses2.1%71.0069.0069.0074.0076.00
  R&D Expenses9.0%175161148139143
Net Income-9.6%-220-201-184-186-192
Net Income Margin-43.2%-11.18*-7.81*-5.80*-6.50*-
Free Cahsflow-3.1%-181-176-170-173-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-3.1%514531581623677
  Current Assets-16.4%357427461497507
    Cash Equivalents-32.8%142211169211204
  Net PPE0.5%16.0015.0016.0017.0017.00
Liabilities32.1%154116115110124
  Current Liabilities42.1%60.0042.0036.0037.0047.00
Shareholder's Equity-13.0%361415465513554
  Retained Earnings-7.8%-1,078-1,000-961-908-857
  Additional Paid-In Capital0.4%1,4421,4361,4301,4231,412
Shares Outstanding0.1%69.0069.0069.0069.0068.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-4.5%-177,349-169,658-162,439-163,551-163,803
  Share Based Compensation-7.3%29,29431,58735,71842,62643,399
Cashflow From Investing-3.9%114,068118,756-10,132-1,339-54,466
Cashflow From Financing-25.4%1,2841,7224,13820,853282,106

Risks for EDIT

What is the probability of a big loss on EDIT?

100%


Probability that Editas Medicine stock will be more than 20% underwater in next one year

88.8%


Probability that Editas Medicine stock will be more than 30% underwater in next one year.

78.1%


Probability that Editas Medicine stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EDIT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Editas Medicine was unfortunately bought at previous high price.

Drawdowns

Returns for EDIT

Cumulative Returns on EDIT

-17.0%


7-Year Cumulative Returns

-26.0%


5-Year Cumulative Returns

-24.2%


3-Year Cumulative Returns

What are the long-term rolling returns for EDIT?

FIve years rolling returns for Editas Medicine.

Annualized Returns

Which funds bought or sold EDIT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
sold off
-100
-132,000
-
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-9.33
-79,000
152,000
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-89,827
236,173
-%
2023-02-27
Parallax Volatility Advisers, L.P.
reduced
-96.22
-1,158,400
32,597
-%
2023-02-24
NATIXIS
new
-
23,647
23,647
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-24,000
-
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
reduced
-99.68
-2,991
9.00
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
added
5.63
-671
4,329
-%
2023-02-16
GHP Investment Advisors, Inc.
unchanged
-
-226
1,774
-%
2023-02-15
Financial Advocates Investment Management
sold off
-100
-943,000
-
-%

1–10 of 42

Latest Funds Activity

Are funds buying EDIT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own EDIT
No. of Funds

Editas Medicine News

Best Stocks

Brokerages have issued a consensus recommendation of "Hold" on ....

Best Stocks,
2 hours ago

Editas Medicine

Schedule 13G FIlings of Editas Medicine

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
10.00%
6,873,123
SC 13G/A
Feb 03, 2023
state street corp
13.41%
9,222,236
SC 13G/A
Jan 26, 2023
blackrock inc.
10.7%
7,338,742
SC 13G/A
Jan 20, 2023
blackrock inc.
10.7%
7,338,742
SC 13G/A
Jul 11, 2022
state street corp
11.48%
7,879,890
SC 13G/A
Mar 09, 2022
vanguard group inc
10.69%
7,328,042
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
3.91%
2,675,235
SC 13G/A
Feb 09, 2022
vanguard group inc
9.76%
6,673,897
SC 13G/A
Feb 09, 2022
ark investment management llc
6.17%
4,218,302
SC 13G/A
Feb 04, 2022
sumitomo mitsui trust holdings, inc.
3.91%
2,675,235
SC 13G/A

EDIT Fair Value

Editas Medicine fair value in different scenarios

The table shows the Fair Value estimates for Editas Medicine for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

1.28

-84.92%

1.31

-84.57%

1.40

-83.51%

1.55

-81.74%

1.88

-77.86%
Current Inflation

1.28

-84.92%

1.31

-84.57%

1.38

-83.75%

1.52

-82.10%

1.81

-78.68%
Very High Inflation

1.27

-85.04%

1.30

-84.69%

1.37

-83.86%

1.48

-82.57%

1.72

-79.74%

Historical Editas Medicine Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Editas Medicine

View All Filings
Date Filed Form Type Document
Mar 14, 2023
8-K
Current Report
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Feb 22, 2023
10-K
Annual Report
Feb 22, 2023
8-K
Current Report
Feb 22, 2023
S-8
Employee Benefits Plan
Feb 15, 2023
4
Insider Trading
Feb 15, 2023
4
Insider Trading

Latest Insider Trading transactions for EDIT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-03
Eaton Bruce
sold
-897
8.89
-101
evp, cbo and cto
2023-03-03
ROBERTSON MICHELLE
sold
-1,635
8.89
-184
evp, chief financial officer
2023-03-02
Mei Baisong
acquired
-
-
18,000
svp, chief medical officer
2023-03-02
O'Neill Gilmore Neil
acquired
-
-
50,000
ceo
2023-03-02
ROBERTSON MICHELLE
acquired
-
-
31,500
evp, chief financial officer
2023-03-02
Eaton Bruce
acquired
-
-
16,700
evp, cbo and cto
2023-02-13
ROBERTSON MICHELLE
sold
-41,435
9.6653
-4,287
evp, chief financial officer
2023-02-13
Eaton Bruce
sold
-31,963
9.6653
-3,307
evp, cbo and cto
2023-02-13
Shearman Mark S
sold
-26,966
9.6653
-2,790
evp, chief scientific officer
2023-02-07
Eaton Bruce
sold
-3,840
11.1
-346
evp, cbo and cto

1–10 of 50

James C. Mullen
260
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Consolidated Statements of Operations   
Collaboration and other research and development revenues$ 19,712$ 25,544$ 90,732
Revenue typeus-gaap:ServiceMemberus-gaap:ServiceMemberus-gaap:ServiceMember
Operating expenses:   
Research and development$ 174,958$ 142,507$ 157,996
General and administrative70,70476,18367,576
Total operating expenses245,662218,690225,572
Operating loss(225,950)(193,146)(134,840)
Other income, net:   
Other income (expense), net1,293(1,698)16,259
Interest income, net4,2252,3422,605
Total other income, net5,51864418,864
Net loss(220,432)(192,502)(115,976)
Net loss, basic(220,432)(192,502)(115,976)
Net loss, diluted$ (220,432)$ (192,502)$ (115,976)
Net loss per share, basic (in dollars per share)$ (3.21)$ (2.85)$ (1.98)
Net loss per share, diluted (in dollars per share)$ (3.21)$ (2.85)$ (1.98)
Weighted-average common shares outstanding, basic (in shares)68,664,82267,619,38858,609,389
Weighted-average common shares outstanding, diluted (in shares)68,664,82267,619,38858,609,389

EDIT Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 141,522$ 203,519
Marketable securities202,752296,326
Accounts receivable5,145267
Prepaid expenses and other current assets7,3357,198
Total current assets356,754507,310
Marketable securities93,097120,071
Property and equipment, net15,56917,118
Right-of-use assets43,64826,173
Restricted cash and other non-current assets5,2536,811
Total assets514,321677,483
Current liabilities:  
Accounts payable9,5115,050
Accrued expenses31,29620,192
Deferred revenue, current8,22111,333
Operating lease liabilities11,08210,309
Total current liabilities60,11046,884
Operating lease liabilities, net of current portion32,86416,069
Deferred revenue, net of current portion60,66760,888
Total liabilities153,641123,841
Stockholders' equity  
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 68,847,382 and 68,489,257 shares issued, and 68,847,382 and 68,435,257 shares outstanding at December 31, 2022 and December 31, 2021, respectively77
Additional paid-in capital1,442,4051,411,827
Accumulated other comprehensive loss(3,601)(493)
Accumulated deficit(1,078,131)(857,699)
Total stockholders' equity360,680553,642
Total liabilities and stockholders' equity$ 514,321$ 677,483